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ABSTRACT 
Targeted radiotherapy using [
131
I]meta-iodobenzylguanidine ([
131
I]MIBG) 
has produced remissions in some neuroblastoma patients.  We previously 
reported that combining [
131
I]MIBG with the topoisomerase I (Topo-I) 
inhibitor topotecan induced long-term DNA damage and supra-additive 
toxicity to NAT-expressing cells and xenografts.  This combination 
treatment is undergoing clinical evaluation.  This present study investigated 
the potential of PARP-1 inhibition, in vitro and in vivo, to further enhance 
[
131
I]MIBG/topotecan efficacy.  
 
Methods: Combinations of topotecan and the PARP-1 inhibitor PJ34 were 
assessed for synergism in vitro by combination-index analysis in SK-N-
BE(2c) (neuroblastoma) and UVW/NAT (NAT-transfected glioma) cells.  
Three treatment schedules were evaluated: topotecan administered (1) 24 h 
before, (2) 24 h after, or (3) simultaneously with PJ34.  Using similar 
scheduling, combinations of PJ34 & [
131
I]MIBG and PJ34 & 
[
131
I]MIBG/topotecan were also assessed.  In vivo efficacy was measured by 
growth delay of tumour xenografts.  We also assessed DNA damage by 
H2AX assay, cell cycle progression by FACS analysis and PARP-1 
activity in treated cells. 
 
Results:  In vitro, only simultaneous administration of topotecan and PJ34 
or PJ34 and [
131
I]MIBG induced supra-additive toxicity in both cells lines.  
All scheduled combinations of PJ34 & [
131
I]MIBG/topotecan induced supra-
additive toxicity and increased DNA damage in SK-N-BE(2c) cells, but 
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only simultaneous administration induced enhanced efficacy in UVW/NAT 
cells.  PJ34 & [
131
I]MIBG/topotecan combination treatment induced G2 
arrest in all cell lines, regardless of the schedule of delivery.  In vivo, 
simultaneous administration of PJ34 & [
131
I]MIBG/topotecan significantly 
delayed the growth of SK-N-BE(2c) and UVW/NAT xenografts compared 
to [
131
I]MIBG/topotecan therapy. 
 
Conclusion:  The anti-tumor efficacy of topotecan, [
131
I]MIBG and 
[
131
I]MIBG/topotecan combination treatment was increased by PARP-1 
inhibition in vitro and in vivo. 
 
 4 
 Neuroblastoma is a heterogeneous disease, and using age, stage and 
other biological characteristics, patients can be assigned to various risk 
groups (1)  There is evidence that, over time, outcomes are gradually 
improving (2).  However, for patients with high-risk disease, outcomes 
remain poor (3, 4) and innovative therapies are required, especially for those 
whose disease fails to respond well to induction chemotherapy (5). 
Approximately 90% of neuroblastoma tumour cells e xpress the 
noradrenaline transporter (NAT), a 12-spanning integral membrane protein 
responsible for the active intracellular accumulation of catecholamine 
neurotransmitters.  Meta-iodobenzylguanidine (MIBG), a derivative of the 
adrenergic neurone-blocking drugs bretylium and guanethidine, is a 
structural analogue of noradrenaline, and is also selectively concentrated in 
NAT-expressing tissues and tumours by this process (6, 7).   
Targeted therapy of neuroblastoma using [
131
I]MIBG has produced 
encouraging results (long-term remissions and palliation) in patients with 
resistant disease (8-10).  However, the most effective way to use this drug 
has yet to be defined and, increasingly, [
131
I]MIBG is administered in 
combination with other treatments (11-12).  Optimisation of radiation 
damage induced in target cells can be obtained by rational combination of 
[
131
I]MIBG with radiosensitising agents, and we have previously reported 
that pretreatment with the topoisomerase I (Topo-I) poison topotecan 
increased the intracellular concentration of [
131
I]MIBG (13).  Furthermore, 
we demonstrated that combinations of [
131
I]MIBG and topotecan induced 
disruption of DNA repair in NAT-expressing cells in vitro, supra-additive 
levels of cytotoxicity, and increased efficacy against NAT-expressing 
 5 
xenografts in vivo.  Maximal topotecan-induced radiosensitisation resulted 
from the administration of the drug simultaneously with, or following 
[
131
I]MIBG.  Exposure to topotecan prior to [
131
I]MIBG was less effective 
(14, 15), suggesting that increased [
131
I]MIBG uptake due to prior topotecan 
administration was less important an influence on efficacy as the increased 
disruption of DNA repair observed in cells treated by combination 
schedules where topoisomerase I was inhibited concurrently, or following 
[
131
I]MIBG administration.  
On the basis of our findings, clinical investigations of MATIN 
(MIBG And Topotecan In Neuroblastoma) have commenced (16).  To date, 
more than 70 patients in 5 institutions across Europe have received MATIN.  
Encouraging responses have been observed in a heterogeneous group of 
patients with relapsed or primary refractory disease.  It is our intention to 
further enhance the effectiveness of MATIN by identifying other clinically 
relevant drugs which synergise with either topotecan, [
131
I]MIBG, or with 
both agents. 
Poly(ADP-ribose) polymerase (PARP-1) is an enzyme involved in 
DNA repair (17, 18) and it has been demonstrated that PARP-1 inhibition 
enhanced the efficacy of low dose radiation (19).  Furthermore, PARP-1 
binds directly to Topo-I, leading to increased formation of Topo-I–DNA 
complexes (20).  Therefore,we conjectured that PARP-1 inhibition may also 
influence topotecan-induced toxicity.  This study investigated the effects of 
PARP-1 inhibition on the efficacy of topotecan, [
131
I]MIBG and 
[
131
I]MIBG/topotecan combination therapy. 
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MATERIALS AND METHODS   
Drugs 
Topotecan (topoisomerase I inhibitor) was purchased from Axxora (UK) 
Ltd, and PJ34 (PARP-1 inhibitor) from Merck Chemicals Ltd.  For in vitro 
experiments, no-carrier-added [
131
I]MIBG was provided by Dr S Pimlott, 
NHS Greater Glasgow and Clyde.  For in vivo experiments, no-carrier-
added [
131
I]MIBG was provided by Molecular Insight Pharmaceuticals Inc 
(Cambridge, Massachusetts, USA). 
 
Cells and Culture Conditions 
The following human cell lines were cultured: SK-N-BE(2c), derived from 
neuroblastoma (21), and UVW/NAT, derived by transfection of the 
noradrenaline transporter gene into the human glioma cell line UVW (22).  
UVW/NAT cells were maintained in MEM containing 10% foetal calf 
serum and 2 mM glutamine.  SK-N-BE(2c) cells were maintained in 
DMEM containing 15% foetal calf serum, non-essential amino acids, 2 mM 
glutamine.  Cell lines were maintained at 37
o
C in a 5% CO2 atmosphere.  
All media and supplements were purchased from Gibco (Paisley, UK).  Cell 
lines were authenticated routinely using the Applied Biosystems AmpF/STR 
Identifiler Kit (Applied Biosystems UK). 
 
No-carrier-added Synthesis of [131I]MIBG via Polymer Supported 
Precursor  
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For in vivo experiments, no-carrier-added [
131
I]MIBG was prepared 
using a solid-phase system where the precursor of [
131
I]MIBG was attached 
to an insoluble polymer via the tin-aryl bond (23, 24).  For in vitro 
experiments, no-carrier-added [
131
I]MIBG was prepared using a liquid 
phase system, using the trimethylsily precursor (ABX, Germany) (25). The 
reaction conditions, HPLC purification procedure, and radiochemical yield 
were as described previously (24). 
 
Determination of Cytotoxicity Following Combination Therapy 
In order to investigate the effects of PARP-1 inhibition on 
[
131
I]MIBG/topotecan therapy, initially combinations of topotecan and PJ34 
were evaluated using three treatment schedules: topotecan administered 24 h 
before (1), after (2) or simultaneously with (3) PJ34. 
Using similar scheduling, combinations of PJ34 & [
131
I]MIBG and 
triple combinations of PJ34 & [
131
I]MIBG/topotecan were also evaluated..  
As we have already reported that administration of [
131
I]MIBG and 
topotecan induced supra-additive responses, in the assessment of PJ34, 
[
131
I]MIBG and topotecan 3-drug combinations, PJ34 was administered 24 h 
before (1), after (2) or simultaneously with (3) [
131
I]MIBG and topotecan 
given simultaneously. 
Cytotoxicity was measured by clonogenic assay.  Monolayers of 
cells were cultured in 25cm
2
 flasks (Nunclon Plastics, Denmark).  
UVW/NAT and SK-N-BE(2c) cells were seeded at 2 x 10
5
 and 4 x 10
5
 cells 
per flask respectively.  After two days, when the cultures were 70% 
confluent, medium was removed and replaced with fresh medium 
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containing the appropriate concentration of test drug.  Cells were incubated 
with [
131
I]MIBG for 2 hours, after which uptake is maximal (26).  Cells 
were incubated with topotecan and/or PJ34 for 24 hours. 
After experimental therapy, cells were washed twice in phosphate 
buffered saline (PBS), detached by treatment with 0.05 % (v/v) trypsin-
EDTA (Gibco, Paisley, UK), counted and seeded, in triplicate, in 60 x 
15mm plastic dishes (Nunclon Plastics, Denmark) at 2.5 x 10
2
 cells per dish, 
for every test concentration.  Cultures were incubated at 37
o
C in 5% CO2 for 
14 days.  Colonies were fixed in 100% methanol, and visualised by staining 
with a solution of 1 % (v/v) Giemsa (BDH Laboratory Supplies) and 
counted. 
 
Synergy Analysis 
The efficacy of the various scheduled combinations was examined 
according to the method of Chou and Talalay, which is based on the 
median-effect principle (27).  Briefly, from the results of clonogenic assays, 
dose-effect curves were plotted using the equation log[fa/fu] = mlogD - 
mlogIC50, where D is the drug dose, fa and fu are, respectively, the fraction 
of cells affected by drug dose D and the unaffected fraction and IC50 is the 
dose which inhibited 50% of colony formation.  From these survival plots, 
the x-intercept (log [IC50]) and slope m were generated for each treatment.  
These parameters were used to calculate D, the doses of component agents 
(and combinations) required to produce various levels of toxicity. 
The effectiveness of combination therapy was then assessed by 
combination-index analysis (27).  The toxicities induced by single drugs and 
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scheduled combinations were investigated using the equation CI = 
(D)1/(Dx)1 + (D)2/(Dx)2, where (D)1 and (D)2 are the doses of each agent 
which inhibit x% of cell growth when used in combination and (Dx)1 and 
(Dx)2 are the doses of each drug, administered as single agents, which 
inhibit x% of colonies.  The resultant numerical values, the combination 
indices were plotted against toxicity level. 
 
Assessment of Cell Cycle Progression by FACS Analysis. 
Cells were plated in 25cm
2
 flasks and exposed to single drug and 
multi-drug combinations as described above.  In order to directly compare 
the effects on cell cycle progression to the results of clonogenic assay, the 
same drug concentrations and incubation times were used.  Cultures were 
then trypsinised, counted, washed twice with PBS and resuspended in PBS 
at a concentration of 1 x 10
6
 cells/ml.  Cells were fixed by treatment with 
75% (v/v) ethanol for 1 h at 4
o
C.  Fixed cells were washed twice with PBS 
and resuspended in 1ml PBS containing 50 mg/ml propidium iodide (Sigma 
chemicals, Dorset UK) and 5 μg/ml RNase A (Qiagen Ltd. W. Sussex, UK).  
Cells were stained for 3 h at 4
o
C before flow cytometry, using a FACScan 
analyser (Becton Dickinson Systems, Cowley, UK).  Data were analysed 
using BD CellQuest Pro software, version 5.1.1.   
 
Assessment of Double-strand (ds) DNA Breaks by H2A.X 
Phosphorylation 
Phosphorylation of histone H2A.X at serine 139 (H2A.X) was 
assessed using the H2A.X Phosphorylation Assay Kit (Millipore, Herts. 
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UK).  Briefly, cells were seeded and drug-treated, as described above.  
Immediately following treatment, when DNA damage was expected to be 
maximal, cells were trypsinised, counted, washed twice with PBS and fixed 
by addition of formaldehyde/methanol for 20 min at 4
o
C.  Cells were then 
washed three times with PBS and resuspended, at a concentration of 2 x 10
6
 
cells/ml, in permeabilization solution (5% saponin, 100 mM HEPES pH 7.4, 
1.4 M NaCl, 25 mM CaCl2) containing anti-phospho-histone H2A.X 
(Ser139)-FITC conjugate for 20 min at 4
o
C.  Fluorescence was measured 
using a FACScan analyser (Becton Dickinson Systems, Cowley, UK).  Data 
were analysed using BD CellQuest Pro software, version 5.1.1.   
 
PARP-1 Assay 
 Cellular PARP-1 activity was assessed using the commercially 
available HT Universal colorimetric assay kit (AMS Biotechnology Ltd, 
Abingdon UK), according to the manufacturers instructions.  Briefly, 
following drug treatment as described above, PARP-1 activity was assayed 
by incorporation of biotinylated poly(ADP-ribose) onto histone proteins, 
followed by incubation with streptavidin-horseradish peroxidase and TACS-
sapphire colorimetric substrate.  Absorbance at 450nm was measured using 
a Sunrise plate reader (Tecan UK Ltd, reading UK), with Magellan CE 
software (v 5.04). 
 
Experimental Animals.  
Six-week-old female, congenitally athymic nude mice of strain MF1 
nu/nu were obtained from Charles River plc (Kent, United Kingdom). 
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Experiments were carried out in accordance with the UK Co-ordinating 
Committee on Cancer Research guidelines (28). 
 
In Vivo Investigations 
SK-N-BE(2c) and UVW/NAT xenografts were established and 
analysed as previously described (14, 15).  Briefly, SK-N-BE(2c) xenografts 
were established by intrasplenic injection of 3 x 10
6
 exponentially growing 
cells.  Following the growth of tumours in the spleen and liver, animals 
were euthanized and tumour fragments 2-3 mm in diameter were then 
implanted subcutaneously in the subcostal flanks of other nude mice.  
Experimental therapy commenced 17 days after tumour implantation when 
tumours had reached approximately 10 mm diameter (500 mm
3
).  
UVW/NAT xenografts were established by subcutaneous injection of 2 x 
10
6
 cells.  Experimental therapy was initiated 9 days later, when tumor 
volume was approximately 60 mm
3
.   
Groups of 6 mice with SK-N-BE(2c) or UVW/NAT tumours were 
randomized into six treatment groups which received, by intraperitoneal 
(i.p.) injection, (a) saline (control), (b) 20 mg/kg PJ34 alone, (c) 18 MBq of 
[
131
I]MIBG + 1.75 mg/kg of topotecan (SK-N-BE(2c)), or 5 MBq of 
[
131
I]MIBG + 0.825 mg/kg of topotecan (UVW/NAT) or (d) PJ34 given 
simultaneously with [
131
I]MIBG/topotecan. 
Experimental xenografts were measured with calipers immediately 
prior to treatment and every 2-3 days thereafter.  Measurements were 
converted to an approximate volume on the assumption of ellipsoidal 
geometry as previously described (14, 15). 
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For each treatment group, the mean time taken for a 2-fold (T2) (SK-
N-BE(2c)) or 10-fold (T10) (UVW/NAT) increase in tumours was 
calculated.  Tumour cure was defined as the failure of experimental 
xenografts to increase in size over the experimental time course. 
 
Statistical Analysis  
Unless otherwise stated, experimental results are expressed as means 
and standard deviations of three separate experiments, carried out in 
triplicate.  Statistical analyses were carried out using GraphPad Prism 
software, version 4.03 (GraphPad software Inc.).  One-way analysis of 
variance (ANOVA) was used to compare, between treatments, formation of 
dsDNA damage and PARP-1 activity.  Post hoc testing used Bonferroni’s 
correction for multiple comparisons.  Differences in tumour growth between 
experimental therapy groups were assessed by the Kruskal-Wallis test, 
followed by post hoc testing by the Mann-Whitney U test.  With 
Bonferroni’s correction, P < 0.01667 was considered significant. 
 
 
RESULTS   
Cytotoxicity of 2-drug Combination Therapy 
For both cell lines, the efficacy of topotecan and PJ34 as single 
agents was assessed, and results were plotted graphically, according to the 
median-effect principle (Supplementary Figure 1A).  On the basis of single 
drug toxicity, a fixed ratio of topotecan : PJ34 was used in subsequent 
analyses of alternative combination schedules The topotecan (nM): PJ34 
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(μM) ratios were 8.8 : 31.97 for SK-N-BE(2c) cells; and 10 : 29.1 for 
UVW/NAT cells.  The median-effect plots for alternative topotecan/PJ34 
combination schedules are shown in Supplementary Figure 1B.   
Combination-index analysis of topotecan & PJ34 treatments in (A) 
SK-N-BE(2c) and (B) UVW/NAT cells are shown in Figure 1.  Both cell 
lines were resistant to doses of combinations of topotecan & PJ34 which 
induced low levels of toxicity.  Schedule (3) (topotecan & PJ34 
simultaneously) was the most effective treatment, inducing supra-additive 
responses in both lines.  In SK-N-BE(2c) cells, supra-additive responses 
were also observed following schedule (2) treatment (topotecan after PJ34, 
but not schedule (1) (topotecan before PJ34).  All three schedules induced 
supra-additivity in UVW/NAT cells at high levels of toxicity. 
Dose-responses for PJ34 and [
131
I]MIBG as single agents are shown 
in Supplementary Figure 2A.  On the basis of these results, the ratios of 
PJ34 (μM): [131I]MIBG (MBq/ml) used in subsequent combination studies 
were 31.97 : 1.29 for SK-N-BE(2c) cells; and 29.1 : 2.76 for UVW/NAT 
cells..  The effects of scheduled combinations are shown in Supplementary 
Figure 2B.  The resultant combination-index analyses of (A) SK-N-BE(2c) 
and (B) UVW/NAT cells are shown in Figure 2. 
Both cell lines were resistant to doses of combinations of PJ34 & 
[
131
I]MIBG which induced low levels of toxicity.  Schedule (3) (PJ34 & 
[
131
I]MIBG simultaneously) induced supra-additive responses in both cell 
lines.  In SK-N-BE(2c) cells, schedule (1) (PJ34 before [
131
I]MIBG) 
induced an additive response, whereas schedule (2) (PJ34 after [
131
I]MIBG) 
induced infra-additive toxicity.  In UVW/NAT cells, supra-additive 
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responses were also observed following administration of schedule (2), 
whereas schedule (1) induced infra-additive toxicity. 
 
Cytotoxicity of 3-drug Combination Therapy 
Dose-responses for PJ34 as a single agent and [
131
I]MIBG/topotecan 2-drug 
combinations are shown in Supplementary Figure 3A.  On the basis of these 
results, the ratios of PJ34 (μM) : [131I]MIBG (MBq/ml) : topotecan (nM) 
used in subsequent 3-drug combination studies were 31.97 : 1.29 : 8.8 for 
SK-N-BE(2c) cells; and 29.1 : 2.76 : 10 for UVW/NAT cells.  Therefore 1 
arbitrary dose unit (au) contained 0.76 uM PJ34, 0.03 MBq/ml [
131
I]MIBG 
and 0.21 nM topotecan or 0.69 uM PJ34, 0.07 MBq/ml [
131
I]MIBG and 0.24 
nM topotecan for SK-N-BE(2c) and UVW/NAT cells respectively. 
The effects of scheduled triple combinations are shown in 
Supplementary Figure 3B.  The resultant combination-index analyses of (A) 
SK-N-BE(2c) and (B) UVW/NAT cells are shown in Figure 3. 
Supra-additive toxicity was observed in SK-N-BE(2c) cells 
following all three schedules at every level of toxicity assessed.  Only 
schedule (3) (PJ34 & [
131
I]MIBG/topotecan simultaneously) induced 
enhanced efficacy in UVW/NAT cells.  Schedule (2) (PJ34 after 
[
131
I]MIBG/topotecan) induced an additive response in UVW/NAT cells, 
whereas schedule (1) (PJ34 before [
131
I]MIBG/topotecan) was antagonistic. 
 
Cell Cycle Redistribution 
Cell cycle redistribution induced by PJ34 in SK-N-BE(2c) and 
UVW/NAT cells is shown in Table 1.  The effects of triple combination 
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treatments upon cell cycle phases are shown in Table 2 (SK-N-BE(2c)) and 
Table 3 (UVW/NAT).  PJ34 as a single agent induced G2/M arrest.  
Likewise, all three scheduled combinations of PJ34 & [
131
I]MIBG/topotecan 
caused an increase in the number of cells in G2/M. 
 
H2A.X Analysis of dsDNA Damage 
 The effects of 3-drug administration on formation of dsDNA breaks 
are shown in Figure 4A. Cells treated with PJ34 & [
131
I]MIBG/topotecan 
combinations displayed increased phosphorylation of H.2AX foci compared 
to untreated controls.  In SK-N-BE(2c) cells, all treatment schedules 
induced a 28-45-fold increase in dsDNA damage.  Analysis of variance 
demonstrated no significant difference between the potency of alternative 
combination schedules.  However, in UVW/NAT cells, administration of 
alternative schedules gave rise to various levels of DNA damage.  Schedule 
(1) induced a 2-fold increase in H2A.X foci, whereas schedule (3) induced 
a 60-fold increase.  Schedule (2) induced a 20-fold increase in H2A.X 
phosphorylation.  Analysis of variance demonstrated significant variation 
between the responses induced by alternative schedules of delivery and in 
post-hoc testing, Schedule (3) induced significantly higher levels of 
γH2A.X phosphorylation than either of the other treatment schedules (p < 
0.01667). 
 
PARP-1 Activity 
 The effects of (i) PJ34 treatment and (ii) [
131
I]MIBG/topotecan 2-
drug therapy on PARP-1 activity in SK-N-BE(2c) and UVW/NAT cells are 
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shown in Figure 4B.  PJ34 induced a dose-dependent reduction in PARP-1 
activity compared to untreated controls.  SK-N-BE(2c) cells were more 
sensitive to PJ34 than UVW/NAT cells.  The dose which reduced PARP-1 
activity by 50% (EC50) was 8.8 μM and 14.6 μM, in SK-N-BE(2c) cells and 
UVW/NAT cells respectively. 
In SK-N-BE(2c) cells, compared with untreated controls, 
administration of [
131
I]MIBG/topotecan induced a reduction in PARP-1 
activity at concentrations less than, or equal to 21.03 au.  
[
131
I]MIBG/topotecan also reduced PARP-1 activity in UVW/NAT cells at 
concentrations less than, or equal to 20.93 au.  As with PJ34, SK-N-BE(2c) 
cells were more sensitive to [
131
I]MIBG/topotecan than UVW/NAT cells 
(EC20 values were 6.8 au and 14.5 au for SK-N-BE(2c) and UVW/NAT 
cells respectively).  However, in both cell lines, following administration of 
the highest administered dose of [
131
I]MIBG/topotecan (31.55 au for SK-N-
BE(2c) cells; 31.39 au for UVW/NAT cells), 100% recovery of PARP-1 
activity was observed, suggesting an adaptive response to 
[
131
I]MIBG/topotecan-induced disruption of PARP-1 function. 
 The effects of PJ34 & [
131
I]MIBG/topotecan combination therapy on 
PARP-1 activity in (i) SK-N-BE(2c) and (ii) UVW/NAT cells are shown in 
Figure 4C.  3-drug therapy reduced PARP-1 activity in SK-N-BE(2c) cells 
compared to untreated controls.  Schedule (3) (simultaneous administration) 
was the most effective schedule.  However, unlike [
131
I]MIBG/topotecan 2-
drug therapy, there was no recovery in PARP-1 activity at higher doses in 
SK-N-BE(2c) cells.  In UVW/NAT cells, administration of Schedules (2) & 
(3) (PJ34 simultaneously with, or after [
131
I]MIBG/topotecan) also induced 
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a reduction in PARP-1 activity.  Again, there was no evidence of a recovery 
of PARP-1 function at higher doses.  However, Schedule (1) (PJ34 before 
[
131
I]MIBG/topotecan) had no effect on PARP-1 activity.  This suggests that 
inhibition of PARP-1 function by PJ34 was not only reversed after removal 
of the drug, but provoked resistance to subsequent [
131
I]MIBG/topotecan-
induced inhibition of PARP-1 function in this cell line. 
 
In Vivo Investigations 
None of the animals in this study showed signs of distress. Figure 5 
shows the effect, on the growth of (A) SK-N-BE(2c) and (B) UVW/NAT 
tumor xenografts, of the administration of PJ34 or [
131
I]MIBG/topotecan 
either alone or in combination.  Tumor growth times and cure rates for SK-
N-BE(2c) and UVW/NAT xenografts are presented in Table 4. 
 For both xenograft models, overall differences in the effectiveness of 
the different treatments were highly significant (Kruskal-Wallis test, P < 
0.005).  Single treatment with PJ34 did not significantly affect tumour 
growth.  Treatment with [
131
I]MIBG/topotecan or PJ34 in combination with 
[
131
I]MIBG/topotecan significantly delayed SK-N-BE(2c) and UVW/NAT 
tumor growth compared to PBS treated controls (P < 0.01667).  
Furthermore, 3-drug therapy also significantly increased the delay in tumour 
growth compared to [
131
I]MIBG/topotecan double combinations in both in 
vivo models (P < 0.01667).  No SK-N-BE(2c) tumors were cured during the 
course of these experiments.  In contrast, 60% of UVW/NAT tumors were 
cured by [
131
I]MIBG/topotecan treatment, whereas 3-drug treatment cured 
all UVW/NAT tumors. 
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DISCUSSION 
Previously, we reported that topotecan (topoisomerase I inhibitor) 
synergised with [
131
I]MIBG.  The present study indicated that PJ34 
enhanced the efficacy of topotecan and [
131
I]MIBG in vitro, and 
[
131
I]MIBG/topotecan combination therapy in vitro and in vivo.  Enhanced 
[
131
I]MIBG/topotecan efficacy was associated with disruption of PARP-1 
activity, increased formation of dsDNA breaks and G2/M cell cycle arrest. 
Enhanced efficacy was most likely caused by disruption of DNA 
damage repair pathways.  PARP-1 is involved in the repair of single-strand 
DNA breaks through the base excision repair (BER) pathway (29) and may 
also be involved in repair of double-strand breaks, through the homologous 
recombination (HR) pathway (30).  Furthermore, we have previously 
demonstrated that topotecan and [
131
I]MIBG, either alone or in combination, 
induced G2-phase cell cycle arrest (15).  In this study, treatment with PJ34 
either as a single agent, or in combination with [
131
I]MIBG/topotecan, also 
caused G2 arrest.  Cells in G2- and M-phase are more radiosensitive than 
cells in cells in other phases of the cell cycle (31).  Thus cell cycle 
redistribution induced by treatment with  PJ34 & [
131
I]MIBG/topotecan 
combinations probably contributed to the enhanced efficacy of [
131
I]MIBG. 
Following topotecan treatment, Topo-I becomes strongly associated 
with DNA via stabilisation of Topo-I–DNA complexes, leading to stalled 
DNA replication.  PARP-1-mediated ADP-ribosylation of Topo-I 
reprograms the trapped enzyme to remove itself from cleaved DNA (32).  
PARP-1 also collaborates with Mre11, a core subunit of the 
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Mre11/Rad50/Nbs1 damage recognition complex, to promote replication 
fork restart after release from replication blocks (30).  Thus, by 
counteracting topoisomerase I-induced DNA damage, PARP-1 activity acts 
as a positive regulator of genomic stability in eukaryotic cells.   
It has previously been demonstrated that following the induction of 
DNA damage by X-ray, UV and gamma irradiation, binding of PARP-1 to 
Topo-I induces a rapid sequestration of Topo-I onto the sites of the DNA 
lesions (33-35).  Furthermore, Topo-I-mediated unwinding of supercoiled 
DNA is reduced following irradiation, possibly by abrogation of Topo-I 
catalytic activity (36, 37), or reduced longevity of Topo-I–DNA complexes 
(38).  This effect appears to be due to PARP-1-induced ADP-ribosylation of 
Topo-I, and is prevented by the addition of PARP-1 inhibitors (36, 37), 
Therefore, in cells treated with combinations of [
131
I]MIBG and 
topotecan, inhibition of PARP-1 activity by PJ34 leads to the simultaneous 
generation of multiple effects.  Deregulation of Topo-I function via ADP-
ribosylation and prevention of removal of topotecan-mediated aberrant 
Topo-I-DNA adducts will enhance the efficacy of the Topo-I poison, while 
disruption of BER and potentially, HR mechanisms of repair would increase 
the effects of [
131
I]MIBG-induced DNA damage. 
Treatment with [
131
I]MIBG/topotecan induced a reduction in PARP-
1 activity, reaching a nadir at a combination dose equivalent to 21.03 au and 
20.93 in SK-N-BE(2c) and UVW/NAT cells respectively.  It has long been 
recognised that MIBG is an inhibitor of mono-ADP-ribosylation (39).  
Furthermore, it has recently been suggested that, in the absence of DNA 
damage, PARP-1 function is regulated by the mono-ADP-ribosyl 
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polymerase activity of the related enzyme PARP-3 (40).  Therefore, one 
possible explanation for these findings is that reduced PARP-1 function 
following administration of low doses of [
131
I]MIBG/topotecan is due to 
MIBG-induced inhibition of PARP-3 regulation of PARP-1.  However, 
following administration of doses of [
131
I]MIBG/topotecan greater than 
21.03 au (SK-N-BE(2c)) or 20.93 au (UVW/NAT), PARP-1 function 
recovered in and both cell lines.  Increased DNA damage was observed with 
increasing dose of 3-drug therapy.  Taken together, these results suggest that 
if, as speculated, MIBG inhibits PARP-3, increasing DNA damage may 
induce activation of PARP-1 via a PARP-3-independent pathway, leading to 
the observed recovery of PARP-1 function after high-dose 
[
131
I]MIBG/topotecan treatment. 
UVW/NAT cells treated with PJ34 prior to [
131
I]MIBG/topotecan 
displayed no disruption of PARP-1 function.  PJ34 induced a reduction of 
PARP-1 activity, which was restored by removal of the drug.  The 
subsequent addition of [
131
I]MIBG/topotecan had no effect on PARP-1 
function, suggesting that UVW/NAT cells were primed to resist 
[
131
I]MIBG/topotecan-induced disruption of PARP-1 activity by PJ34 pre-
treatment.  It is possible that the recovery of PARP-1 function in PJ34 pre-
treated cells may be induced by a PARP-3-independent pathway which 
would be unaffected by PARP-3 inhibition by MIBG.  This suggests that the 
efficacy of PJ34/[
131
I]MIBG/topotecan treatment may be affected by 
alternative PARP-1 activation pathways and warrants further study. 
While the involvement of PARP-1 in repair of dsDNA damage is as yet 
unclear, this present study does suggest that PARP-1 activity is involved in 
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this process in some way.  SK-N-BE(2c) cells, which exhibited reduced 
PARP-1 function in this phase, also displayed increased generation of 
dsDNA damage following 3-drug treatment, leading to supra-additive 
cytotoxicity.  Conversely, UVW/NAT cells treated with PJ34 prior to 
[
131
I]MIBG/topotecan exhibited normal PARP-1 function and DNA damage 
was negligible, suggesting less inhibition of the repair of dsDNA breaks, 
leading to infra-additive toxicity in cells treated by this schedule.  
Combination therapy also induced G2/M arrest, where the predominant 
dsDNA damage repair pathway is HR.  Therefore it is possible that PARP-1 
may play a role in HR, however involvement with non-homologous end 
joining (NHEJ) cannot be discounted. 
PJ34 alone induced cytotoxicity and G2/M arrest.  Therefore, non-
target effects may influence overall response.  This will be addressed by 
further mechanistic studies, utilising PJ34 and also second- and third-
generation inhibitors with greater PARP-1 specificity. 
Previously, we demonstrated that [
131
I]MIBG/topotecan combination 
therapy significantly inhibited SK-N-BE(2c) and UVW/NAT tumor growth 
in vivo (14, 15).  In this study, while PJ34 treatment had no effect on tumour 
growth, administration of PJ34 concurrently with [
131
I]MIBG/topotecan 
significantly delayed the growth of SK-N-BE(2c) and UVW/NAT 
xenografts compared to [
131
I]MIBG/topotecan.   
  
CONCLUSION 
This study indicates that inhibition of PARP-1 has the potential to increase 
the efficacy of [
131
I]MIBG/topotecan combination therapy, by increasing 
 22 
radiosensitivity and disrupting DNA repair.  Taking into account the 
responses observed both in vitro and in vivo, this study suggests that 
enhancement of [
131
I]MIBG/topotecan efficacy may be best achieved by the 
simultaneous inhibition of PARP-1 function.  Elucidation of the basis for 
resistance following pre-treatment with PJ34 may allow further refinements 
to this combination and are worthy of investigation. 
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FIGURE LEGENDS 
 
Figure 1 
Combination index analysis of PJ34/topotecan combination treatment in (A) 
SK-N-BE(2c) and (B) UVW/NAT cells.  Based on the results shown in 
Supplementary Figure 1, SK-N-BE(2c) were treated with topotecan and 
PJ34 in a ratio of 8.8 : 31.97.  UVW/NAT were treated with PJ34 and 
topotecan in a ratio of 10 : 29.1.  Data are means and standard deviations of 
triplicate determinations from three experiments.  CI < 1, CI = 1, and CI > 1 
indicate synergism, additivity and antagonism respectively.   
 
Figure 2 
Combination index analysis of PJ34/[
131
I]MIBG combination treatment in 
(A) SK-N-BE(2c) and (B) UVW/NAT cells.  Based on the results shown in 
Supplementary Figure 2, SK-N-BE(2c) were treated with PJ34 and 
[
131
I]MIBG in a ratio of 31.97 : 1.29.  UVW/NAT were treated with PJ34 
and [
131
I]MIBG in a ratio of 29.1 : 2.76.  Data are means and standard 
deviations of triplicate determinations from three experiments.  CI < 1, CI = 
1, and CI > 1 indicate synergism, additivity and antagonism respectively. 
 
Figure 3 
Combination index analysis of PJ34/[
131
I]MIBG/topotecan combinations in 
(A) SK-N-BE(2c) and (B) UVW/NAT cells.  Based on the results shown in 
Supplementary Figure 3, SK-N-BE(2c) were treated with PJ34, [
131
I]MIBG 
and topotecan in a ratio of 31.97 : 1.29 : 8.8.  UVW/NAT were treated with 
PJ34, [
131
I]MIBG and topotecan in a ratio of 29.1 : 2.76 : 10.  Data are 
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means and standard deviations of triplicate determinations from three 
experiments.  CI < 1, CI = 1, and CI > 1 indicate synergism, additivity and 
antagonism respectively. 
 
Figure 4 
A. γH2A.X analysis of dsDNA damage in (i) SK-N-BE(2c) and (ii) 
UVW/NAT cells.  B. PARP-1 activity in SK-N-BE(2c) and UVW/NAT 
cells following (i) PJ34 and (ii) [
131
I]MIBG/topotecan treatment.  C. PARP-
1 activity in (i) SK-N-BE(2c) and (i) UVW/NAT cells following PJ34 & 
[
131
I]MIBG/topotecan combination treatment.  The ratios of PJ34 and 
[
131
I]MIBG/topotecan used in 2-drug and 3-drug combinations were as 
described in figure 3.  Data are means and standard deviations of triplicate 
determinations from three experiments. 
 
Figure 5 
The effects of PJ34 and [
131
I]MIBG/TPT on (A) SK-N-BE(2c) and (B) 
UVW/NAT xenografts.  Each treatment group consisted of six animals.  
Mice bearing SK-N-BE(2c) xenografts were treated with either 20mg/kg 
PJ34, 18MBq [
131
I]MIBG + 1.75mg/kg topotecan or combinations of PJ34 
and [
131
I]MIBG/topotecan.  UVW/NAT-bearing animals were treated with 
either 20mg/kg PJ34, 5MBq [
131
I]MIBG + 0.875 mg/kg topotecan or 3-drug 
combinations. 
